AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11532411 — intervention group
Group type: COMPARATOR
Intervention: Medical students
Number of subjects: 20
Study 9263195 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 0
Study 9263195 — intervention group
Group type: COMPARATOR
Intervention: Saccharin (50 mg)
Number of subjects: 0
Study 8198625 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium (800 mg/day) + vitamin D3 placebo
Number of subjects: 58
Study 8198625 — intervention group
Group type: EXPERIMENTAL
Intervention: vitamin D3 (5 micrograms/day) + calcium placebo
Number of subjects: 58
Study 8198625 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium + vitamin D3
Number of subjects: 58
Study 8198625 — intervention group
Group type: COMPARATOR
Intervention: placebo treatment
Number of subjects: 58
Study 3733916 — intervention group
Group type: EXPERIMENTAL
Intervention: Detached attitude
Number of subjects: 0
Study 3733916 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved attitude
Number of subjects: 0
Study 31391139 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutionally-reared children
Number of subjects: 188
Study 31391139 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutionalization
Number of subjects: 188
Study 31391139 — intervention group
Group type: COMPARATOR
Intervention: Never-institutionalized children
Number of subjects: 188
Study 31391139 — intervention group
Group type: EXPERIMENTAL
Intervention: EF assessment
Number of subjects: 188
Study 30514434 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Schema Displacement Therapy (VSDT)
Number of subjects: 105
Study 30514434 — intervention group
Group type: EXPERIMENTAL
Intervention: abbreviated EMDR protocol
Number of subjects: 105
Study 30514434 — intervention group
Group type: COMPARATOR
Intervention: Control Condition (CC)
Number of subjects: 105
Study 28403360 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (RMGIC) (Fuji ORTHO LC)
Number of subjects: 29
Study 28403360 — intervention group
Group type: EXPERIMENTAL
Intervention: Light cured composite resin (Transbond XT)
Number of subjects: 29
Study 28403360 — intervention group
Group type: COMPARATOR
Intervention: Topical application of 1.23% acidulated phosphate fluoride (APF)
Number of subjects: 29
Study 26177348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac group)
Number of subjects: 72
Study 26177348 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA group)
Number of subjects: 72
Study 23635560 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly administration of paclitaxel, carboplatin, and trastuzumab (12 doses over 16 weeks)
Number of subjects: 56
Study 23635560 — intervention group
Group type: COMPARATOR
Intervention: Every-3-weeks administration of paclitaxel, carboplatin, and trastuzumab (4 doses over 12 weeks)
Number of subjects: 56
Study 23635560 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly administration in luminal-B (HER2-positive) tumors
Number of subjects: 56
Study 23635560 — intervention group
Group type: COMPARATOR
Intervention: Every-3-weeks administration in luminal-B (HER2-positive) tumors
Number of subjects: 56
Study 23635560 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly administration in ERBB2+ tumors
Number of subjects: 56
Study 23635560 — intervention group
Group type: COMPARATOR
Intervention: Every-3-weeks administration in ERBB2+ tumors
Number of subjects: 56
Study 21501803 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention (educational institution-based peer education, teacher training, community peer education, health information materials)
Number of subjects: 0
Study 21501803 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention (in rural community)
Number of subjects: 0
Study 21501803 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention (in urban community)
Number of subjects: 0
Study 21501803 — intervention group
Group type: EXPERIMENTAL
Intervention: Information materials
Number of subjects: 0
Study 21501803 — intervention group
Group type: EXPERIMENTAL
Intervention: Community peer education
Number of subjects: 0
Study 21501803 — intervention group
Group type: EXPERIMENTAL
Intervention: Institution-based interventions
Number of subjects: 0
Study 18505646 — intervention group
Group type: COMPARATOR
Intervention: Amalgam (negative control)
Number of subjects: 75
Study 18505646 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid resin composite (TPH, Dentsply) with prior acid conditioning and bonding with an etch-and-rinse adhesive (Prime&Bond NT, Dentsply)
Number of subjects: 75
Study 18505646 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacid-modified resin composite (Dyract, Dentsply) bonded with Prime&Bond NT
Number of subjects: 75
Study 18505646 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract with prior nonrinse conditioner (NRC) treatment and bonding with Prime&Bond NT
Number of subjects: 75
Study 18505646 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacid-modified resin composite (F2000) in conjunction with a self-etch adhesive (Prompt-L-Pop, 3M/ESPE)
Number of subjects: 75
Study 17172172 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with a complex containing Ester-C with antioxidants (2100 mg of Ca-ascorbate + 340 mg of bioflavonoids)
Number of subjects: 18
Study 17172172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15522042 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping mechanography
Number of subjects: 258
Study 15522042 — intervention group
Group type: COMPARATOR
Intervention: Chair-rising test
Number of subjects: 258
Study 11155094 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR (3 injections at 4 week intervals)
Number of subjects: 27
Study 11155094 — intervention group
Group type: COMPARATOR
Intervention: Lanreotide (5 injections at 14 day intervals)
Number of subjects: 27
Study 9125696 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light-Caffeine
Number of subjects: 4
Study 9125696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim Light-Caffeine
Number of subjects: 4
Study 9125696 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light-Placebo
Number of subjects: 4
Study 9125696 — intervention group
Group type: COMPARATOR
Intervention: Dim Light-Placebo
Number of subjects: 4
Study 8103112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of moxisylyte
Number of subjects: 12
Study 8103112 — intervention group
Group type: COMPARATOR
Intervention: Intracavernous administration of moxisylyte
Number of subjects: 12
Study 3756776 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (cyclophosphamide, vincristine, and prednisone [CVP], five courses)
Number of subjects: 113
Study 3756776 — intervention group
Group type: COMPARATOR
Intervention: Whole‐abdominal irradiation (25 Gy/20 Fr)
Number of subjects: 113
Study 29390245 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 29
Study 29390245 — intervention group
Group type: EXPERIMENTAL
Intervention: Darboepoetin alfa
Number of subjects: 29
Study 29390245 — intervention group
Group type: COMPARATOR
Intervention: Estorclean PLUS
Number of subjects: 29
Study 29390245 — intervention group
Group type: COMPARATOR
Intervention: Intravenous iron therapy with sodium ferrigluconate
Number of subjects: 29
Study 29390245 — intervention group
Group type: EXPERIMENTAL
Intervention: Global savings with epoetin alfa
Number of subjects: 29
Study 29390245 — intervention group
Group type: EXPERIMENTAL
Intervention: Global savings with darboepoetin alfa
Number of subjects: 29
Study 26903081 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body program (8-week group program followed by 6 monthly sessions)
Number of subjects: 282
Study 26903081 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body program
Number of subjects: 282
Study 26903081 — intervention group
Group type: COMPARATOR
Intervention: Health education program (control)
Number of subjects: 282
Study 25487561 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure
Number of subjects: 16
Study 25487561 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 16
Study 23377510 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 5% gel
Number of subjects: 2898
Study 23377510 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 2898
Study 23120716 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley's manoeuvre
Number of subjects: 48
Study 23120716 — intervention group
Group type: EXPERIMENTAL
Intervention: Semont's manoeuvre
Number of subjects: 48
Study 23120716 — intervention group
Group type: EXPERIMENTAL
Intervention: Brandt‐Daroff exercises
Number of subjects: 48
Study 23120716 — intervention group
Group type: EXPERIMENTAL
Intervention: Any of the three manoeuvres
Number of subjects: 48
Study 18525395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillometric blood pressure devices
Number of subjects: 0
Study 18525395 — intervention group
Group type: COMPARATOR
Intervention: Mercury sphygmomanometer
Number of subjects: 0
Study 15593011 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose IPT with SP
Number of subjects: 1163
Study 15593011 — intervention group
Group type: COMPARATOR
Intervention: weekly CQ chemoprophylaxis
Number of subjects: 1163
Study 15593011 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose IPT with CQ
Number of subjects: 1163
Study 11834680 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone, 60 mg/d for 7 days
Number of subjects: 20
Study 11834680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11207478 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin 5% (HA)
Number of subjects: 60
Study 11207478 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine 4% (GEL)
Number of subjects: 60
Study 11207478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch solution 6% (HES)
Number of subjects: 60
Study 11207478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's solution
Number of subjects: 60
Study 9408699 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (750 mg twice a day for 3 months)
Number of subjects: 44
Study 9408699 — intervention group
Group type: COMPARATOR
Intervention: Control (no anti-viral prophylaxis)
Number of subjects: 44
Study 8487654 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration prior to FSIGT
Number of subjects: 0
Study 8487654 — intervention group
Group type: COMPARATOR
Intervention: Saline administration prior to FSIGT
Number of subjects: 0
Study 3104750 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH (thyrotropin-releasing hormone) at 10 mg per kg on alternate days for 3 months
Number of subjects: 12
Study 3104750 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH (thyrotropin-releasing hormone)
Number of subjects: 12
Study 30983412 — intervention group
Group type: EXPERIMENTAL
Intervention: TCTR (Thread Carpal Tunnel Release)
Number of subjects: 20
Study 30983412 — intervention group
Group type: COMPARATOR
Intervention: Control hand
Number of subjects: 20
Study 28470504 — intervention group
Group type: EXPERIMENTAL
Intervention: Food deprivation (short period)
Number of subjects: 0
Study 28470504 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no food deprivation)
Number of subjects: 0
Study 27717393 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month multicomponent intervention including ongoing support, provision of resources, performance monitoring and feedback, executive support and recognition.
Number of subjects: 53
Study 24006239 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 13
Study 24006239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 22315336 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted 3.75-μg HA/AS03(A)
Number of subjects: 1340
Study 22315336 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted formulation (2 doses) or 1 dose of adjuvanted 3.75-μg HA formulation
Number of subjects: 1340
Study 22315336 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 1340
Study 20555305 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic valganciclovir
Number of subjects: 115
Study 20555305 — intervention group
Group type: COMPARATOR
Intervention: Preemptive valganciclovir
Number of subjects: 115
Study 18175736 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein, low-carbohydrate (LC) ketogenic diet
Number of subjects: 17
Study 18175736 — intervention group
Group type: COMPARATOR
Intervention: High-protein, medium-carbohydrate (MC) nonketogenic diet
Number of subjects: 17
Study 16186072 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein containing 99mg isoflavones (aglycone weights)
Number of subjects: 202
Study 16186072 — intervention group
Group type: COMPARATOR
Intervention: Milk protein (placebo)
Number of subjects: 202
Study 14671904 — intervention group
Group type: EXPERIMENTAL
Intervention: Plapherone LB (sublingually, 2 mg protein/day)
Number of subjects: 94
Study 14671904 — intervention group
Group type: COMPARATOR
Intervention: Routine intensive therapy
Number of subjects: 94
Study 10804025 — intervention group
Group type: EXPERIMENTAL
Intervention: Human parathyroid hormone 1-34 (hPTH(1-34)) daily injections for 12 months
Number of subjects: 0
Study 10804025 — intervention group
Group type: EXPERIMENTAL
Intervention: Human parathyroid hormone 1-34 (hPTH(1-34))
Number of subjects: 0
Study 10804025 — intervention group
Group type: COMPARATOR
Intervention: Estrogen-only group (control)
Number of subjects: 0
Study 8956699 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CA 125 concentration > or = 30 U/ml
Number of subjects: 22000
Study 8956699 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CA 125 concentration > 100 U/ml
Number of subjects: 22000
Study 8956699 — intervention group
Group type: COMPARATOR
Intervention: Serum CA 125 concentration < 30 U/ml
Number of subjects: 22000
Study 8956699 — intervention group
Group type: COMPARATOR
Intervention: Entire study population
Number of subjects: 22000
Study 1658962 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 aPTT-U low-molecular-weight heparin plus 0.5 mg dihydroergotamine (Embolex)
Number of subjects: 110
Study 1658962 — intervention group
Group type: COMPARATOR
Intervention: twice daily administration of 5000 IU of the heparin-dihydroergotamine combination (Heparin-Dihydergot)
Number of subjects: 110
Study 1658962 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolex
Number of subjects: 110
Study 1658962 — intervention group
Group type: COMPARATOR
Intervention: Heparin-Dihydergot
Number of subjects: 110
Study 30660687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-processed food consumption at preschool age
Number of subjects: 307
Study 30660687 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 307
Study 28537769 — intervention group
Group type: COMPARATOR
Intervention: KSR2-rs7973260 A allele
Number of subjects: 1788
Study 25663083 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser alone at 975nm (group 1)
Number of subjects: 100
Study 25663083 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser alone at 924/975nm simultaneously (group 2)
Number of subjects: 100
Study 25663083 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage alone (group 3)
Number of subjects: 100
Study 25663083 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser at 924/975nm followed by curettage (group 4)
Number of subjects: 100
Study 23838709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-based anesthesia (group S)
Number of subjects: 193
Study 23838709 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia (group T)
Number of subjects: 193
Study 21092958 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 58
Study 21092958 — intervention group
Group type: COMPARATOR
Intervention: COC
Number of subjects: 58
Study 20041778 — intervention group
Group type: EXPERIMENTAL
Intervention: Red ginseng extract-containing herbal mixture at 3 g/day
Number of subjects: 82
Study 20041778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 17584667 — intervention group
Group type: COMPARATOR
Intervention: Normal group (healthy subjects)
Number of subjects: 20
Study 17584667 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD patients
Number of subjects: 20
Study 15764166 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg daily for 5 days, repeated 3 times with a 23-day interval
Number of subjects: 103
Study 15764166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 15764166 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 103
Study 11774114 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipedal bioelectrical impedance analysis (BIA)
Number of subjects: 0
Study 10723506 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0
Study 10723506 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea + Didanosine (DDI)
Number of subjects: 0
Study 7641514 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physical therapy
Number of subjects: 67
Study 2616205 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine-gum (8-12 gums a day for one month)
Number of subjects: 14
Study 2616205 — intervention group
Group type: COMPARATOR
Intervention: Placebo-gum (8-12 gums a day for one month)
Number of subjects: 14
Study 310339 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined adjuvant immunotherapy (bacillus Calmette‐Guérin and levamisole)
Number of subjects: 0
Study 310339 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 0
Study 31634401 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory continuous theta burst stimulation (cTBS) over right inferior parietal lobe (IPL)
Number of subjects: 20
Study 31634401 — intervention group
Group type: COMPARATOR
Intervention: Placebo over left inferior parietal lobe (IPL)
Number of subjects: 20
Study 30587963 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan and hydrochlorothiazide
Number of subjects: 80
Study 30587963 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan alone
Number of subjects: 80
Study 30587963 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for AECOPD
Number of subjects: 80
Study 28608582 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood leukaemia diagnosed at age 5‐15 years
Number of subjects: 1871
Study 28608582 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute lymphoid leukaemia (ALL) diagnosed at age 0‐4 years
Number of subjects: 1871
Study 28608582 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall childhood leukaemia
Number of subjects: 1871
Study 25447602 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (LDK) infusion (0.2 to 0.4 mg/kg, administered over 10 to 15 minutes)
Number of subjects: 14
Study 25447602 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (LDK) infusion
Number of subjects: 14
Study 22177936 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐rTMS (10 Hz rTMS to the lesional hemisphere)
Number of subjects: 29
Study 22177936 — intervention group
Group type: EXPERIMENTAL
Intervention: LF‐rTMS (1 Hz rTMS to the nonlesional hemisphere)
Number of subjects: 29
Study 22177936 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 29
Study 21315224 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia (TP) group
Number of subjects: 1000
Study 21315224 — intervention group
Group type: COMPARATOR
Intervention: No Thrombocytopenia (non-TP) group
Number of subjects: 1000
Study 19236695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte proliferation assay (LPA) to ESAT-6
Number of subjects: 1885
Study 19236695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte proliferation assay (LPA) to Ag85
Number of subjects: 1885
Study 19236695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte proliferation assay (LPA) to Mycobacterium tuberculosis whole cell lysate (WCL)
Number of subjects: 1885
Study 19236695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST)
Number of subjects: 1885
Study 19236695 — intervention group
Group type: EXPERIMENTAL
Intervention: ESAT-6 LPA
Number of subjects: 1885
Study 19236695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ag85 LPA
Number of subjects: 1885
Study 19236695 — intervention group
Group type: EXPERIMENTAL
Intervention: WCL LPA
Number of subjects: 1885
Study 16702898 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 948
Study 15110926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol infusion
Number of subjects: 24
Study 15110926 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without PMDD)
Number of subjects: 24
Study 10778252 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient groups (95 women)
Number of subjects: 199
Study 10778252 — intervention group
Group type: COMPARATOR
Intervention: Control group (96 women)
Number of subjects: 199
Study 10778252 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative life events
Number of subjects: 199
Study 9264500 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindoprilat (5 nmol/mL)
Number of subjects: 8
Study 8405850 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid yeast sucrase
Number of subjects: 14
Study 8405850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3093468 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 83
Study 3093468 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 83
Study 3093468 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 83
Study 31877310 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant removal of colorectal polyps during the insertion phase
Number of subjects: 220
Study 31877310 — intervention group
Group type: COMPARATOR
Intervention: Control group (polyp removal during withdrawal phase)
Number of subjects: 220
Study 29405819 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebound therapy exercise (10-30 minutes, three sessions a week for 12 weeks)
Number of subjects: 16
Study 27613125 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-mounted display-assisted teaching
Number of subjects: 14
Study 27613125 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 14